← Back to Search

Hormone Therapy

Insulin for Insulin Resistance

Phase < 1
Waitlist Available
Led By Jacqueline L Limberg, Ph.D.
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline at minute 60
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is studying whether high levels of insulin in the blood can reduce the narrowing of blood vessels in the legs caused by the nervous system. The research involves human subjects and aims to understand how insulin affects blood flow. This could be important for people with conditions like diabetes.

Eligible Conditions
  • Insulin Resistance
  • Vasoconstriction
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at minute 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at minute 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amount of leg blood flow
Secondary study objectives
Amount of cerebral blood flow
Amount of muscle sympathetic nerve activity (MSNA)

Side effects data

From 2015 Phase 4 trial • 156 Patients • NCT02002221
13%
Nasopharyngitis
10%
Hyperhidrosis
9%
Hunger
9%
Tremor
8%
Asthenia
6%
Hypoglycaemia
1%
Femoral neck fracture
1%
Squamous cell carcinoma of the tongue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vildagliptin (LAF237)
Placebo

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: InsulinExperimental Treatment1 Intervention
Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Insulin human
FDA approved

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
379 Previous Clinical Trials
628,466 Total Patients Enrolled
10 Trials studying Insulin Resistance
336 Patients Enrolled for Insulin Resistance
Jacqueline L Limberg, Ph.D.Principal InvestigatorUniversity of Missouri-Columbia
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top